Poliovirus vaccines in mineral oil adjuvant: II. Clinical reaction and antibody response

Purified aqueous poliovirus vaccine containing a total of 4.6γ of viral substance per dose was highly effective in immunizing very young infants against poliovirus. Eighty-three, 55, and 84 per cent of infants responded serologically with neutralizing antibody when given three doses of vaccine in th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of allergy 1963-09, Vol.34 (5), p.420-425
Hauptverfasser: Stone, Shirley, Hu, Rose, Krugman, Saul, Tytell, Alfred A., Hilleman, Maurice R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 425
container_issue 5
container_start_page 420
container_title The Journal of allergy
container_volume 34
creator Stone, Shirley
Hu, Rose
Krugman, Saul
Tytell, Alfred A.
Hilleman, Maurice R.
description Purified aqueous poliovirus vaccine containing a total of 4.6γ of viral substance per dose was highly effective in immunizing very young infants against poliovirus. Eighty-three, 55, and 84 per cent of infants responded serologically with neutralizing antibody when given three doses of vaccine in the primary series. Essentially all responded with high titer when the booster dose of vaccine was given 7 months later. Emulsified mineral oil adjuvant vaccine, containing only 0.46γ of viral antigen per dose and given in only two doses, effected seroconversion of 52 per cent, 42 per cent, and 48 per cent of infants to poliovirus types I, II, and III, following the primary immunization series and 90 per cent, 80 per cent, and 87 per cent, respectively, were converted to the three types following the booster dose. Even better results would likely have been obtained had three doses been given initially. A generally poorer antibody response was obtained with the use of Salk vaccine than with the aqueous and adjuvant purified vaccines. None of the infants developed significant local or systemic reaction to the vaccine. Roughly, 30 children were included in each of the three vaccine groups in the study.
doi_str_mv 10.1016/0021-8707(63)90006-6
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_83261691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0021870763900066</els_id><sourcerecordid>83261691</sourcerecordid><originalsourceid>FETCH-LOGICAL-e179t-a95c2e09172dacc07c7b2ced573f4fe15e32d1da511594c03cb16c5c1bbba42a3</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhnNQbP34ByI5iR62Zja72a4HQYofhYIeFLyFbDKFlG1Sk92F_ntTWz0MM7zzMvPyEHIJbAIMxB1jOWTTilU3gt_WjDGRiSMy_pdH5DTGFWO8qll5QkZQMCH4tBiTr3ffWj_Y0Ec6KK2tw0ito-s0BNVSb1uqzKoflOvu6Xw-obPWOqvTKqDSnfWOKmdSdbbxZpvUuPEu4jk5Xqo24sWhn5HP56eP2Wu2eHuZzx4XGUJVd5mqS50jq6HKTXrPKl01uUZTVnxZLBFK5LkBo0qAsi4047oBoUsNTdOoIlf8jFzv726C_-4xdnJto8a2VQ59H-WU5wJEDcl4dTD2zRqN3AS7VmEr_1gkw8PegCnuYDHIqC26FMYG1J003kpgcgdc7sjKHVkpuPwFnoYfVRh0QQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83261691</pqid></control><display><type>article</type><title>Poliovirus vaccines in mineral oil adjuvant: II. Clinical reaction and antibody response</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Stone, Shirley ; Hu, Rose ; Krugman, Saul ; Tytell, Alfred A. ; Hilleman, Maurice R.</creator><creatorcontrib>Stone, Shirley ; Hu, Rose ; Krugman, Saul ; Tytell, Alfred A. ; Hilleman, Maurice R.</creatorcontrib><description>Purified aqueous poliovirus vaccine containing a total of 4.6γ of viral substance per dose was highly effective in immunizing very young infants against poliovirus. Eighty-three, 55, and 84 per cent of infants responded serologically with neutralizing antibody when given three doses of vaccine in the primary series. Essentially all responded with high titer when the booster dose of vaccine was given 7 months later. Emulsified mineral oil adjuvant vaccine, containing only 0.46γ of viral antigen per dose and given in only two doses, effected seroconversion of 52 per cent, 42 per cent, and 48 per cent of infants to poliovirus types I, II, and III, following the primary immunization series and 90 per cent, 80 per cent, and 87 per cent, respectively, were converted to the three types following the booster dose. Even better results would likely have been obtained had three doses been given initially. A generally poorer antibody response was obtained with the use of Salk vaccine than with the aqueous and adjuvant purified vaccines. None of the infants developed significant local or systemic reaction to the vaccine. Roughly, 30 children were included in each of the three vaccine groups in the study.</description><identifier>ISSN: 0021-8707</identifier><identifier>DOI: 10.1016/0021-8707(63)90006-6</identifier><identifier>PMID: 14066384</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvants, Immunologic ; Adjuvants, Pharmaceutic ; Antibody Formation ; Humans ; Infant ; Infant, Newborn ; Mineral Oil ; Old Medline ; Poliovirus ; Poliovirus Vaccines</subject><ispartof>The Journal of allergy, 1963-09, Vol.34 (5), p.420-425</ispartof><rights>1963</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14066384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stone, Shirley</creatorcontrib><creatorcontrib>Hu, Rose</creatorcontrib><creatorcontrib>Krugman, Saul</creatorcontrib><creatorcontrib>Tytell, Alfred A.</creatorcontrib><creatorcontrib>Hilleman, Maurice R.</creatorcontrib><title>Poliovirus vaccines in mineral oil adjuvant: II. Clinical reaction and antibody response</title><title>The Journal of allergy</title><addtitle>J Allergy</addtitle><description>Purified aqueous poliovirus vaccine containing a total of 4.6γ of viral substance per dose was highly effective in immunizing very young infants against poliovirus. Eighty-three, 55, and 84 per cent of infants responded serologically with neutralizing antibody when given three doses of vaccine in the primary series. Essentially all responded with high titer when the booster dose of vaccine was given 7 months later. Emulsified mineral oil adjuvant vaccine, containing only 0.46γ of viral antigen per dose and given in only two doses, effected seroconversion of 52 per cent, 42 per cent, and 48 per cent of infants to poliovirus types I, II, and III, following the primary immunization series and 90 per cent, 80 per cent, and 87 per cent, respectively, were converted to the three types following the booster dose. Even better results would likely have been obtained had three doses been given initially. A generally poorer antibody response was obtained with the use of Salk vaccine than with the aqueous and adjuvant purified vaccines. None of the infants developed significant local or systemic reaction to the vaccine. Roughly, 30 children were included in each of the three vaccine groups in the study.</description><subject>Adjuvants, Immunologic</subject><subject>Adjuvants, Pharmaceutic</subject><subject>Antibody Formation</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Mineral Oil</subject><subject>Old Medline</subject><subject>Poliovirus</subject><subject>Poliovirus Vaccines</subject><issn>0021-8707</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1963</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LAzEQhnNQbP34ByI5iR62Zja72a4HQYofhYIeFLyFbDKFlG1Sk92F_ntTWz0MM7zzMvPyEHIJbAIMxB1jOWTTilU3gt_WjDGRiSMy_pdH5DTGFWO8qll5QkZQMCH4tBiTr3ffWj_Y0Ec6KK2tw0ito-s0BNVSb1uqzKoflOvu6Xw-obPWOqvTKqDSnfWOKmdSdbbxZpvUuPEu4jk5Xqo24sWhn5HP56eP2Wu2eHuZzx4XGUJVd5mqS50jq6HKTXrPKl01uUZTVnxZLBFK5LkBo0qAsi4047oBoUsNTdOoIlf8jFzv726C_-4xdnJto8a2VQ59H-WU5wJEDcl4dTD2zRqN3AS7VmEr_1gkw8PegCnuYDHIqC26FMYG1J003kpgcgdc7sjKHVkpuPwFnoYfVRh0QQ</recordid><startdate>196309</startdate><enddate>196309</enddate><creator>Stone, Shirley</creator><creator>Hu, Rose</creator><creator>Krugman, Saul</creator><creator>Tytell, Alfred A.</creator><creator>Hilleman, Maurice R.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>196309</creationdate><title>Poliovirus vaccines in mineral oil adjuvant: II. Clinical reaction and antibody response</title><author>Stone, Shirley ; Hu, Rose ; Krugman, Saul ; Tytell, Alfred A. ; Hilleman, Maurice R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e179t-a95c2e09172dacc07c7b2ced573f4fe15e32d1da511594c03cb16c5c1bbba42a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1963</creationdate><topic>Adjuvants, Immunologic</topic><topic>Adjuvants, Pharmaceutic</topic><topic>Antibody Formation</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Mineral Oil</topic><topic>Old Medline</topic><topic>Poliovirus</topic><topic>Poliovirus Vaccines</topic><toplevel>online_resources</toplevel><creatorcontrib>Stone, Shirley</creatorcontrib><creatorcontrib>Hu, Rose</creatorcontrib><creatorcontrib>Krugman, Saul</creatorcontrib><creatorcontrib>Tytell, Alfred A.</creatorcontrib><creatorcontrib>Hilleman, Maurice R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stone, Shirley</au><au>Hu, Rose</au><au>Krugman, Saul</au><au>Tytell, Alfred A.</au><au>Hilleman, Maurice R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poliovirus vaccines in mineral oil adjuvant: II. Clinical reaction and antibody response</atitle><jtitle>The Journal of allergy</jtitle><addtitle>J Allergy</addtitle><date>1963-09</date><risdate>1963</risdate><volume>34</volume><issue>5</issue><spage>420</spage><epage>425</epage><pages>420-425</pages><issn>0021-8707</issn><abstract>Purified aqueous poliovirus vaccine containing a total of 4.6γ of viral substance per dose was highly effective in immunizing very young infants against poliovirus. Eighty-three, 55, and 84 per cent of infants responded serologically with neutralizing antibody when given three doses of vaccine in the primary series. Essentially all responded with high titer when the booster dose of vaccine was given 7 months later. Emulsified mineral oil adjuvant vaccine, containing only 0.46γ of viral antigen per dose and given in only two doses, effected seroconversion of 52 per cent, 42 per cent, and 48 per cent of infants to poliovirus types I, II, and III, following the primary immunization series and 90 per cent, 80 per cent, and 87 per cent, respectively, were converted to the three types following the booster dose. Even better results would likely have been obtained had three doses been given initially. A generally poorer antibody response was obtained with the use of Salk vaccine than with the aqueous and adjuvant purified vaccines. None of the infants developed significant local or systemic reaction to the vaccine. Roughly, 30 children were included in each of the three vaccine groups in the study.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>14066384</pmid><doi>10.1016/0021-8707(63)90006-6</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0021-8707
ispartof The Journal of allergy, 1963-09, Vol.34 (5), p.420-425
issn 0021-8707
language eng
recordid cdi_proquest_miscellaneous_83261691
source MEDLINE; Alma/SFX Local Collection
subjects Adjuvants, Immunologic
Adjuvants, Pharmaceutic
Antibody Formation
Humans
Infant
Infant, Newborn
Mineral Oil
Old Medline
Poliovirus
Poliovirus Vaccines
title Poliovirus vaccines in mineral oil adjuvant: II. Clinical reaction and antibody response
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A43%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poliovirus%20vaccines%20in%20mineral%20oil%20adjuvant:%20II.%20Clinical%20reaction%20and%20antibody%20response&rft.jtitle=The%20Journal%20of%20allergy&rft.au=Stone,%20Shirley&rft.date=1963-09&rft.volume=34&rft.issue=5&rft.spage=420&rft.epage=425&rft.pages=420-425&rft.issn=0021-8707&rft_id=info:doi/10.1016/0021-8707(63)90006-6&rft_dat=%3Cproquest_pubme%3E83261691%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=83261691&rft_id=info:pmid/14066384&rft_els_id=0021870763900066&rfr_iscdi=true